ClinicalTrials.gg
Not yet recruitingNCT07605442Updated Nov 17, 2026

Cardiometabolic Effects of Low-Fat and Full-Fat Dairy

An interventional study of Full-fat dairy and Low-fat dairy in Cardiovascular (CV) Risk, sponsored by Penn State University. Not yet recruiting. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Penn State University · Not applicable, Interventional, and Other

How we know

Updated Nov 17, 2026Study documents postedStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to find out if full-fat dairy and low-fat dairy have similar effects on risk factors for heart disease and diabetes. During the study, participants will consume two types of dairy products: low-fat dairy (milk, yogurt, and cheese) and full-fat dairy (milk, yogurt, and cheese). Each type of dairy will be consumed for 6 weeks with a ≥4-week break between. Measures will be taken to evaluate blood cholesterol, blood sugar, body weight, inflammation, blood pressure, heart health and dietary intake at the beginning and end of each 6 week period.

Read the detailed description

The overarching goal of this clinical trial is to characterize and compare the effect of full-fat dairy to low-fat dairy on low density lipoprotein cholesterol (LDL-C) and other cardiometabolic disease (CMD) risk factors in healthy adults and those at risk for CMD. This goal will be achieved with the following objectives:

  1. Characterize the effect of full-fat dairy compared to low-fat dairy on LDL-C and other CMD risk factors in healthy adults and adults at risk for CMD after 6 weeks.
  2. Compare the effect of full-fat dairy to low-fat dairy in healthy adults vs. adults at risk for CMD after 6 weeks.

This clinical trial will test two hypotheses: 1) intake of 3 cup-equivalents/day of full-fat dairy (milk, yogurt \& cheese) has equivalent effects on LDL-C and other CMD risk factors to 3 cup-equivalents/day of low-fat dairy (milk, yogurt \& cheese) in adults with normal BMI and optimal/near optimal LDL-C, and in adults with overweight/obesity and elevated LDL-C after 6 weeks; 2) the effect of full-fat dairy on LDL-C and other CMD risk factors, compared to low-fat dairy, is equivalent in adults with normal BMI and optimal/near optimal LDL-C compared to adults with overweight/obesity and elevated LDL-C after 6 weeks. This trial is expected to demonstrate equivalent effects of full-fat and low-fat dairy on LDL-C and other CMD risk factors in both healthy and at-risk adults.

This is a randomized clinical trial with 2 groups of adults. Group 1 will include adults with normal BMI (18.5 -24.9 kg/m2) and optimal/near optimal LDL-C (≤ 129 mg/dL). Group 2 will include adults with overweight/obesity (25-39.9 kg/m2) and elevated LDL-C (130-190 mg/dL). Within each group, subjects will undergo two 6-week dietary conditions in random sequence order, separated by a 4-week washout: 1) 3 cup-equivalents/day of full-fat dairy; 2) 3 cup-equivalents/day of low-fat dairy. Outcomes will be assessed at the start and end of each period.

02

Conditions studied

  • Cardiovascular (CV) Risk

Keywords

  • dairy
  • diet
  • nutrition
  • LDL-cholesterol
  • cardiovascular disease
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 178 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18.5 to 39.9 kg/m2
  • LDL-C ≤190 mg/dL assessed by the Modified Sampson-NIH Equation
  • Currently consume milk, yogurt, and/or cheese daily
  • Willing to eat 3 servings of dairy (milk, yogurt, cheese) for two 6-week periods during the study

Exclusion criteria

Exclusion Criteria:

  • \<13.2 g/dL for men or \< 11.7 g/dL for women at screening
  • Fasting triglycerides >350 mg/dL at screening
  • ≥10% change in body weight within the 6 months prior to enrollment
  • Blood pressure >140/90 mmHg at screening
  • Fasting glucose ≥126 mg/dL
  • Type 1 or type 2 diabetes
  • Takes any (prescription or over-the-counter) anti-hypertensive, lipid-lowering, glucose-lowering or anti-inflammatory drugs, or drugs that alter body weight
  • Intake of supplements that affect the outcomes of interest (i.e., lipids, blood pressure, glucose, body weight, inflammation and microbiome) and are unwilling to cease during the study period.
  • Unwilling to refrain from starting to take any supplements, vitamins, nutritional products, or health foods that are not prescribed by a doctor for the duration of the study
  • History of liver, kidney, or disease
  • Prior cardiovascular event (e.g., stroke, heart attack)
  • Current pregnancy or intention of pregnancy within the next 12 months
  • Lactation within the prior 6 months
  • Dairy allergy/intolerance/sensitivity/dislike
  • Antibiotic use within the prior four weeks
  • Oral use within the prior four weeks
  • Use of tobacco or nicotine-containing products within the past 6 months
  • History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence)
  • Participation in another clinical trial within 60 days of baseline
  • Currently following a restricted or weight-loss diet
  • Prior bariatric surgery
  • Intake of >14 alcoholic drinks/week and/or not willing to avoid alcohol consumption for 48 hours prior to test visits
  • Does not speak and/or understand English
  • Unwilling to refrain from donating blood and/or plasma during the study
  • Weight \<110 lb
  • Lactose intolerance or sensitivity
  • Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study
  • For individuals taking thyroid medication: abnormal thyroid stimulated hormone (TSH) concentration, or change in dose of thyroid medication within the last 6 months
  • Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
178 participants (estimated)

Study arms

  • Experimental
    Healthy Adults

    Adults with normal BMI (18.5 -24.9 kg/m2) and optimal/near optimal LDL-C (≤ 129 mg/dL).

    Other: Full-fat dairy · Other: Low-fat dairy

  • Experimental
    Adults at risk for cardiometabolic diseases

    Adults with overweight/obesity (25-39.9 kg/m2) and elevated LDL-C (130-190 mg/dL

    Other: Full-fat dairy · Other: Low-fat dairy

Interventions

  • OtherFull-fat dairy

    3 cup-equivalents/day of full-fat dairy (milk, yogurt \& cheese)

  • OtherLow-fat dairy

    3 cup-equivalents/day of low-fat dairy (milk, yogurt \& cheese)

06

What researchers measure

Primary outcomes

  1. LDL-cholesterol change

    Assessed from fasting blood draw expressed in mg/dL. LDL-cholesterol will be calculated via the Modified Sampson-NIH Equation. Change in LDL-cholesterol will be calculated as the mean of the end of intervention measures (i.e., mean of day 1 and day 2 values) minus the mean of the pre-intervention measures (i.e., mean of day 1 and day 2 values).

    Time frame: 6 weeks

Secondary outcomes

  1. Apolipoprotein B change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  2. Triglycerides change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  3. Total cholesterol change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  4. HDL-cholesterol change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  5. non-HDL cholesterol change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  6. Glucose change

    Assessed from fasting blood draw expressed in mg/dL.

    Time frame: 6 weeks

  7. Insulin change

    Assessed from fasting blood draw expressed in micro IU/ml.

    Time frame: 6 weeks

  8. Fructosamine change

    Assessed from fasting blood draw expressed in umol/L.

    Time frame: 6 weeks

  9. Homeostatic model of insulin resistance (HOMA-IR) change

    Calculated from insulin and glucose measured from a fasting blood sample. Calculated as (insulin × glucose) / 22.5

    Time frame: 6 weeks

  10. C-reactive protein change

    Assessed from fasting blood draw expressed in mg/L.

    Time frame: 6 weeks

  11. Body weight change

    Measured in the fasting state using a calibrated electronic scale.

    Time frame: 6 weeks

  12. Brachial systolic and diastolic blood pressure change

    Measured in the fasting state using a SphymoCor Xcel (Atcor Medical)

    Time frame: 6 weeks

  13. Central systolic and diastolic blood pressure change

    Measured in the fasting state using a SphymoCor Xcel (Atcor Medical)

    Time frame: 6 weeks

  14. Carotid-femoral pulse wave velocity change

    Measured in the fasting state using a SphymoCor Xcel (Atcor Medical)

    Time frame: 6 weeks

  15. Diet quality change

    Healthy Eating Index-2020 assessed using 24-hour recalls

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: Study protocol and SAP will be uploaded to clinicaltrials.gov prior to enrollment of the first participant

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 21 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 26, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 8, 2026→Nov 2026
Nov 17, 2026
Documents
Show all 1 update
  1. Nov 17, 2026
    Start date Sep 8, 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07605442
Responsible party
Kristina Petersen PhD, APD, FAHA (Associate Professor, Penn State University) — Principal investigator
First posted
May 26, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Kristina Petersen, PhD
Contact
kup63@psu.edu
814-865-7206
Stacey Meily
Contact
sas117@psu.edu
814-863-8622
Kristina Petersen, PhD
principal investigator · The Pennsylvania State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion